A Phase II Study of Enzalutamide(NSC# 766085) for Patients with Androgen Receptor Positive Salivary Glands
Description: 

To evaluate the rate of best overall response (BOR; by RECIST v1.1) associated with
enzalutamide in patients with AR-positive salivary cancers.

Study Number: 

N 30316

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02749903

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.